规范化吸入激素治疗儿童哮喘疗效分析

The efficacy of standardization treatment by inhaled corticosteroids in children with asthma

目的探讨规范化吸入激素治疗儿童哮喘的疗效。方法收集我院儿科哮喘门诊登记就诊的哮喘患儿128例,分为管理组和非管理组(对照组),随访3年,两组首次就诊时即由我科医师建立门诊档案,对管理组患儿家长进行哮喘规范化教育,根据病情吸入不同剂量的布地奈德或二丙酸倍氯米松,坚持长期维持治疗,而对照组仅于发作期治疗。结果管理组患儿3年内哮喘急性发作次数、旷课天数、住院次数及治疗费用均少于对照组;管理组患儿身高年增长速率及体重年增长速率均高于对照组;两组患儿随访期间不良反应无明显差异。结论通过对哮喘患儿进行规范化吸入激素维持治疗,患儿临床症状可有效控制,哮喘急性发作次数、旷课天数、住院次数及医疗费用降低,规范化治疗的患儿身高及体重年增长率高于未规范化治疗的患儿。规范化吸入激素治疗是一种安全有效的儿童哮喘治疗方法,值得临床推广应用。

Objective To investigate the efficacy of standardization treatment by inhaled corticosteroids in children with asthma. Methods 128 cases of children with asthma from pediatric asthma clinic were divided into management and non- management group （control group）, followed up for 3 years, the two groups established by general practitioner for clinics files, asthma standardized education afforded to the management group parents, according to the condition of different doses of inhaled budesonide or beclomethasone dipropionate, adhered to long-term maintenance therapy,while the control group only afforded asthma acute treatments. Results Acute asthma attacks, the number of days of absenteeism, hospitalization and treatment costs of the management group were less than the number of control group, the annual height and weight growth rates of management group were higher than control group, during follow-up, no significant difference of adverse reactions in both groups. Conclu- sion Through the standardization of inhaled corticosteroids therapy in children with asthma, can effectively control symptoms, reduce asthma exacerbations, absenteeism days, hospitalization and medical expenses ,the height and weight growth rate after standardized treatment is higher than the control group. Standardized inhaled corticosteroid therapy is a safe and effective treat- ment for children with asthma, is worthy for clinical application.